VOR

Vor Biopharma Inc. [VOR] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

VOR Stock Summary

In the News

VOR Financial details

Company Rating
-
Market Cap
129.61M
Income
-115.87M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
168
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-1.38
Forward P/E
-
PEG
0.56
P/S
-
P/B
0.89
P/C
-
P/FCF
-1.63
Quick Ratio
10.4
Current Ratio
10.69
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.73
EPS next Y
-
EPS next Q
-
EPS this Y
-23.58%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-20.41%
-
-
-
-
SMA20
-
SMA50
58.62%
SMA100
64.29%
Inst Own
-
Inst Trans
-
ROA
-50%
ROE
-52%
ROC
-0.59%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.62-5.7
52W High
-72.6%
52W Low
+37%
RSI
50.67
Rel Volume
0.54
Avg Volume
315.34K
Volume
170.29K
Perf Week
3.01%
Perf Month
-17.47%
Perf Quarter
59.3%
Perf Half Y
37.49%
-
-
-
-
Beta
-0.365
-
-
Volatility
0.03%, 0.07%
Prev Close
-2.14%
Price
1.37
Change
-2.84%

Something similar

Top by Market Cap
M&M.NS
NVD.DE
TL0.DE
FB2A.DE
JPM
Same Sector
600079.SS
COG.L
PHBI
PRLD
GNFT
Same Price Range
IDXG
CISO
ANVS
BW
UUU
Similar Market Cap
ELMD
AEXAY
ORTI-B.ST
KLDW
0RNK.L

Company Profile

Healthcare Biotechnology
  • Volume Average 315.34K
  • Market Capitalization 129.61M
  • Employee 168
  • CEO Dr. Robert Ang M.B.A., M.D., MBBS
  • Headquarters Cambridge,MA,US
  • IPO Date 2021-02-05
  • Website https://www.vorbio.com

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.